Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling
APX3330
Indiana University School of Medicine
Filter by:
Bridging population pharmacokinetic and physiologically based pharmacokinetic approaches to evaluate APX3330 disposition
APX3330
Indiana University School of Medicine
Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial
NYXOL
Optometry and Vision Science
Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
APX3330
Inflammatory Bowel Disease 2020
The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease
APX3330
Drug Discovery Today 2020
Phentolamine Mesylate Ophthalmic Solution Provides Long Lasting Pupil Modulation and Improves Visual Acuity
NYXOL
Presented at the Association for Research in Vision and Ophthalmology (Online Video Presentation)
Phentolamine Mesylate Ophthalmic Solution Reduces Time to Recovery of Medically-Induced Mydriasis in a Phase 2 Trial
NYXOL
Presented at the Association for Research in Vision and Ophthalmology (Online Video Presentation)
Ocuphire Pharma – Innovation Showcase
Conference Video Presentations
Presented at the Southeastern Educational Congress of Optometry – Ophthalmology Innovation Summit (Atlanta)
A Phase 1 Study of the APE1 Protein Inhibitor APX3330 in Patients with Advanced Solid Tumors
APX3330
Presented at the American Society of Clinical Oncology (Chicago)
